By John Glenday | Reporter

August 4, 2015 | 1 min read

In a world first the US Food and Drug Administration has approved a 3D-printed drug for medical use, ushering in a new era of customised medication.

Developed with Aprecia’s ZipDose technique SPRITAM is intended for use by patients prescribed with high dosages by employing a water soluble design that can be absorbed into the blood stream in as little as 10 seconds.

Commenting on the drug Don Wetherhold, Aprecia’s chief executive officer, said: “By combining 3DP technology with a highly-prescribed epilepsy treatment, SPRITAM is designed to fill a need for patients who struggle with their current medication experience.”

3D printing technology is becoming an increasingly important tool in scientists armoury with a suite of 3d printed drugs set to emerge over the coming years.

Fda General News United States

More from Fda

View all